- 1 Asymptomatic carriage of *Plasmodium falciparum* in children living in a hyperendemic area occurs
- 2 independently of IgG responses but is associated with a balanced inflammatory cytokine ratio.
- 3 Balotin Fogang^{1,2}, Matthieu Schoenhals¹, Franklin M. Maloba¹, Marie Florence Biabi^{1,3}, Estelle
- 4 Essangui¹, Christiane Donkeu^{1,2}, Glwadys Cheteug^{1,4}, Marie Kapen¹, Rodrigue Keumoe¹, Sylvie
- 5 Kemleu¹, Sandrine Nsango^{1,5}, Douglas H. Cornwall⁶, Carole Eboumbou^{1,5}, Ronald Perraut¹, Rosette
- 6 Megnekou², Tracey J. Lamb*6 and Lawrence S. Ayong*1
- 7 Affiliations:
- 8 ¹ Molecular Parasitology Laboratory, Centre Pasteur du Cameroun, BP 1274 Yaounde, Cameroon
- 9 ² Department of Animal Biology and Physiology of the University of Yaoundé I, BP 812 Yaounde,
- 10 Cameroon
- ³ Department of Biochemistry, University of Douala, BP 24157 Douala, Cameroon
- ⁴ Department of Medical Laboratory Sciences, University of Buea, BP 63 Buea, Cameroon
- 13 ⁵Faculty of Medicine and Pharmaceutical Sciences, University of Douala, BP 2701 Douala,
- 14 Cameroon

- 15 ⁶ Department of Pathology, University of Utah, 15 N Medical Drive, Salt Lake City 84112, USA
- * Co-corresponding authors
- 17 Correspondence to: Tracey Lamb tracey.lamb@path.utah.edu Tel: +1 801 213 2097

Footnote Page

- 20 All authors declare no conflict of interest in this study. This work was supported by a capacity
- 21 building grant from the Institute Pasteur International Division to LSA. This information has
- 22 previously been presented at the American Association for Tropical Medicine and Hygiene Annual
- 23 Meeting in 2019. Correspondence to: Tracey Lamb tracey.lamb@path.utah.edu

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

Abstract

Background: Asymptomatic carriage of infected red blood cells (iRBCs) can be prevalent in communities regardless of transmission patterns and can occur with infection of different Plasmodium species. Clinical immunity dampens the inflammatory responses leading to disease symptoms in malaria. The aim of this study was to define the immunological correlates of asymptomatic carriage of *P. falciparum* in a highly exposed population. Methods: 142 asymptomatic *Plasmodium*-infected individuals greater than 2 years of age without fever (body temperature <37.5°C) were followed weekly for 10 weeks before being treated with artemisinin-based combination treatment (ACT). Plasma levels of 38 cytokines were measured at baseline by Luminex and the quantity and growth inhibitory activities of circulating parasite-reactive antibodies measured. The *Plasmodium* antigen tested included *P. falciparum* merozoite extract (ME) and schizont extract (SE), and the recombinant proteins Erythrocyte binding antigen 175 (EBA-175) and merozoite surface protein 1 (MSP-1₁₉). **Results:** Median levels of IgG against *P. falciparum* EBA-175 and MSP-1₁₉ at baseline were significantly higher in those older than 20 years of age compared with the younger age group and appeared to correlate with better parasite control. Amongst all participants there were no discernible changes in IgG levels over time. Parasite density was higher in the younger age group and associated with IL-10, TNF- α and MCP-1 levels. A balanced IL-10:TNF- α ratio was associated with asymptomatic malaria regardless of age, and balanced ratios of IL-10/TNF-α and IL-10/IFN-γ were the only significant correlate of maintenance of asymptomatic malaria over the course of the study in individuals 20 years of age and younger. **Conclusion**: The above findings indicate that asymptomatic carriage of *P. falciparum* in children living in a hyperendemic area occurs independently of IgG but is associated with a balanced inflammatory cytokine ratio.

Key words: Asymptomatic malaria, *Plasmodium falciparum*, IgG and cytokine levels, TNF- α , IL-

49 10

48

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

Introduction

Malaria is still a significant global health problem with an estimated 249 million cases and 608 000 deaths in 2022 [1]. Although mortality rates from malaria have decreased considerably since the turn of the century [2] this has been paralleled by high increases in proportions of asymptomatic infections, known to contribute significantly to persistent malaria transmission in most endemic countries [3,4]. Asymptomatic infections can persist for weeks to years [5] and untreated P. falciparum infections have been shown persist on average for 6 months, with fluctuations in parasite density over the course of an infection [6,7]. The maintenance of chronic asymptomatic malaria will depend on the host immune response to the blood stage of *Plasmodium* [3]. Anti-parasite immunity directly suppress parasite growth resulting in low infection densities (below the pyrogenic threshold [3,8]) whilst antidisease immunity modulates inflammation-mediated clinical manifestations of the infection. Older children and adults have more cumulative exposure to parasite variants circulating within the community, developing adaptive responses which mediate both anti-parasite and anti-disease immunity [9,10]. However, asymptomatic infections have been documented in younger children < 5 years who are too young to have developed robust adaptive immunity [11]. This suggests that asymptomatic malaria may be differentially controlled by innate and adaptive immune responses depending on age. Anti-parasite immunity which is acquired with age or exposure [12,13], is mediated mainly by antibodies which control parasite replication and mediate clearance of Plasmodium-infected red blood cells (iRBCs) [14–16]. Suppression of inflammation associated with iRBCs depends on the balance between anti- and pro-inflammatory cytokine responses [17,18] and it has been hypothesized that asymptomatic infections are associated with a shift in host immune responses towards an antiinflammatory profile after multiple exposures to malaria [19]. This could occur via a decrease in

97

Immunology of asymptomatic parasitemia 73 levels of pro-inflammatory immune mediators such as IFN-γ, TNF-α, or an increase in anti-74 inflammatory mediators such as IL-10 or TGF-β [18,20–22]. 75 The relative contributions of anti-parasite and anti-disease immunity to the maintenance of persistent asymptomatic *Plasmodium* infections in younger individuals and older individuals remain unclear. 76 77 To determine the immunological associations of chronic asymptomatic malaria in younger (\le 20) 78 years) and older (>20 years) individuals we have undertaken a longitudinal study of highly exposed 79 individuals of all ages with asymptomatic malaria over a 3-month period where we monitored the stability of IgG and cytokine responses. We also examined these responses upon clearance of 80 81 parasites to ascertain which responses depended on the presence of circulating parasites. Our study 82 demonstrates a lack of correlation of iRBC density and IgG responses in individuals ≤20 years old, 83 with an association of parasite carriage with IL-10 and an association of asymptomatic status with a 84 balanced ratio of IL-10:TNF- α and IL-10: IFN- γ . 85 86 Material and methods 87 **Ethics statement** 88 The study protocol was approved by the Cameroon National Ethics Committee for Human Health 89 Research (Ethical clearance N°: 2018/09/1104/CE/CNERSH/SP) and the Ministry of Public Health. 90 Written informed consent was obtained from each participant or parent/guardian of minor participants 91 (< 19 years old) prior to enrolment into the study. Assent was obtained from all children older than 12 years of age. 92 93 Study area and population 94 The study population consisted of individuals of both genders aged at least two years of age and 95 permanently living in one of the five selected villages of the Esse health district, Mefou-et-Afamba 96 Division, Centre Region of Cameroon where malaria transmission is perennial, stable and hyper-

endemic with P. falciparum as the predominant Plasmodium species. The study area has been

described elsewhere [23-25]. The inclusion criteria were: i) obtain the consent of each older

participant or parent or legal guardian for the children, ii) living permanently in the study area, iii)

not pregnant.

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

Study design and participants

This was a longitudinal household-based study that involved 353 individuals. Participants were considered asymptomatic for malaria if positive for *P. falciparum* using multiplex nested PCR in the absence of fever at least forty-eight hours prior to enrolment. Being febrile was assessed based on axillary temperature ≥ 37.5 °C or based on the history of fever as independently confirmed by another household member. All symptomatic individuals (fever + rapid diagnostic test (RDT) +) were treated with ACT-based drugs following recommended national guidelines. Participants with asymptomatic carriage of *Plasmodium* parasites were monitored weekly until they either developed a fever, or until the end of the follow up period at week 16 post-enrolment. Participant follow-up comprised of weekly interviews regarding the occurrence of fever during the past week, measurement of axillary temperatures on each visit, and laboratory testing for malaria at weeks 1, 4, 11 and 16 (PCR and microscopy). All symptomatic cases occurring during the follow-up period were treated with ACT as recommended and excluded from further follow-up. At week 11 post-enrolment all participants with persisting asymptomatic parasitemia were treated as recommended, and monitored for five additional weeks to assess the effect of ACT-based antimalarial treatment on selected host immune responses. Participants with persistent asymptomatic parasitemia 10 weeks following enrolment were considered as persistent asymptomatic malaria whereas those who developed malaria-associated symptoms before week 11 post-enrolment were considered as developing uncomplicated malaria.

Blood sample collection, malaria diagnosis and parasite genotyping

Approximately 3 ml of venous blood was collected in EDTA-coated tubes and used for laboratory testing for malaria and blood hemoglobin levels as well as to obtain plasma for immunological analysis. Plasma was separated from the red blood cell (RBC) pellet by centrifugation (3500 RPM,

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

5 min) and stored at -80 °C until use. Blood hemoglobin levels were assessed using a portable Mission Hb haemoglobinometer (ACON Laboratories, USA). Parasite density (parasites/ul) was determined by microscopic examination of Giemsa-stained thick blood smears. Parasite density was determined based on the number of parasites per at least 200 WBC count on a thick film, assuming a total white blood cell count of 8000 cells/µL of whole blood. A blood slide was considered positive when a concordant result was obtained by at least two independent microscopists and when a discrepancy occurred, a third microscopist was used for confirmation. A slide was considered negative if no parasites were detected after a count of 500 white blood cells. Genomic DNA was extracted from dried blood spots using the Chelex method [26], and used to screen for *Plasmodium* infections by multiplex nested PCR targeting the 18S small subunit rRNA (ssrRNA) genes as previously described [24]. Genotyping of msp2 gene was performed by nested PCR on *P. falciparum* PCR positive samples as previously described [24,27]. Case definitions for the study Participants were defined as asymptomatic if positive for malaria parasites by PCR in the absence of fever at least 48 hours prior to enrolment. Febrile malaria was determined based on RDT, light microscopy or PCR positivity for malaria parasites and axillary temperature ≥ 37.5 °C or a history of fever in the past 48 hours. Those developing uncomplicated malaria were defined as asymptomatic individuals who had developed fever associated with *Plasmodium* infection during the 10-week infection follow-up period, whereas the persistent asymptomatic malaria classification represented the asymptomatic individuals who remained asymptomatic until anti-malarial treatment at the end of the infection follow-up period.

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

Anti-Plasmodium antibody levels and avidity assessment Plasma IgG antibody levels and avidity were determined by indirect ELISA method using P. falciparum Merozoite extract (ME), schizont extract (SE) or the recombinant proteins erythrocyte binding antigen-175 (EBA-175) and Merozoite Surface Protein-119 (MSP119) as coating antigens. ME and SE were isolated from laboratory maintained P. falciparum 3D7 parasites as described previously [28], and used for protein extraction by freeze-thaw fractionation [23,29]. The recombinant protein EBA-175 (F3 region) was obtained from BEI Resources (MRA-1162), whereas P. falciparum MSP1₁₉ was produced using a baculovirus-insect cell expression system [30]. 96-well microplates (F96 CERT-Maxisorp) were coated with each antigen (2 mg/ml of ME and SE, 0.20 mg/ml of EBA-175 and 0.5 mg/ml of MSP-1₁₉) in 0.1 M bicarbonate buffer (for ME, SE and EBA-175) or PBS (for MSP-1₁₉) and incubated overnight at 4°C. Plasma samples were diluted (1/250) in PBS-T/1%BSA and used to measure anti-*Plasmodium* IgG as previously described [23,31]. Plasma from non-exposed European blood donors (10 samples) were used as naive controls and a pool of IgG fractions from adults living in high malaria endemic areas was used as positive controls. Results were expressed as optical-density ratios (OD sample/mean OD naive control). For avidity testing, 100 µL of 8M urea in wash buffer (treated wells) or 100 µL of wash buffer (untreated wells) were added for 15 minutes at room temperature to the respective wells following primary antibody binding as previously described [32]. Avidity indices (AI) were calculated as proportion of bound antibodies following urea treatment (AI = [mean OD of treated wells /mean OD of untreated wells] × 100). Samples with OD ratios > 2, corresponding to mean OD naive control + 3SD were considered as seropositive. In addition, only seropositive samples were used for avidity testing. Growth inhibition assay (GIA) GIA was performed using plasma from endemic and non-endemic individuals as described by Duncan et al. [33]. Briefly, plasma samples were heat inactivated at 56 ° C for 20 min and a 1:20

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

ratio of 50% RBC was added to each sample and incubated at room temperature for 1 h to remove the RBC-reactive antibody. After spinning for 2 min at 13,000 x g to pellet the RBCs, the supernatant was transferred to a 96-well V-bottom plate. Synchronized late trophozoite/early schizont (30-40 h) stages of 3D7 P. falciparum at 0.5% parasitemia were incubated with plasma (1:10 ratio) for 48 h at 37 °C. The GIA harvest (parasite growth) was carried out by SYBR green-I DNA quantification assay [34]. Parasite growth inhibition (GI) activities of plasma antibodies were presented as: GI indices (%) = 100 x [1 - ((OD sample - OD RBC) / (OD parasitized RBC - OD RBC))].

Determination of plasma cytokine levels

Plasma concentrations of 38 immune mediators including interleukin (IL)-1α, IL-1β, IL-1RA, IL-2 IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p40, IL-p70, IL-13, IL-15, IL-17A, interferon (IFN)-α2, IFN-γ, tumor necrosis factor (TNF)-α, lymphotoxin-α (LT-α), IFN-γ induced protein (IP-10), monocyte chemoattractant protein (MCP)-1, MCP-3, macrophage inflammatory protein (MIP)-1α, MIP-1β, Eotaxin, Fractalkine, human growth-regulated oncogene (GRO), Macrophage-derived chemokine (MDC), granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), sCD40L, FMS-like tyrosine kinase 3 ligand (Flt-3L), epidermal growth factor (EGF), fibroblast growth factor 2 (FGF-2), transforming growth factor alpha (TGF-α) and vascular endothelial growth factor (VEGF) were determined by Luminex-based method using the Human Cytokine/Chemokine Magnetic Bead Panel MILLIPLEX MAP Kit (Cat. No. HCYTMAG-60K-PX38, EMD Millipore Corporation) according to the manufacturer's instructions. Briefly, 25 µL of premixed magnetic capture beads were incubated with equal volumes of plasma or diluted standard in a 96-well microplate placed on a horizontal plate shaker for 2 hours. After washing using a magnetic plate, plates were incubated with 25 µL/well of biotinylated detection antibodies for 1 hour at room temperature followed by 25 µL of streptavidin-PE in each well for 30 minutes at room temperature. Median fluorescence intensity was read on a Luminex MAGPIX Analyser (XMAP Technology) equipped with xPONENT software version 4.2. The relative concentration of each

cytokine (pg/ml) in each sample was determined based on the automatically generated standard curve for each analyte. Analyte amounts less than the limit of detection for each cytokine were attributed the value of detection limit.

Statistical analysis

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

Statistical analyses were performed using RStudio version 4.1.1 or version 4.2.2 [35] and Graphpad Prism version 8.4.3 (Graphpad software, San Diego, California USA). Differences in antibody and cytokine distribution between two or more groups were determined using Wilcoxon signed rank test and Kruskal-Wallis test, respectively. Spearman rank correlation tests or linear regression were used to determine the correlation between quantitative variables. Differences in categorical variables were determined by chi-square tests. P-values < 0.05 were considered statistically significant. Factor analysis of mixed data (FAMD) with FactoMineR and factoextra packages was used to assess the association between cytokines levels and age and circulating parasite loads. The complexHeatmap and ggpubr packages were used to draw the heatmaps and the line plots, respectively. Given that the aim of this study was to determine the host immunological determinants in the maintenance of the asymptomatic infections, among the 353 individuals included, only participants with complete information on the study outcome during the longitudinal follow-up period were included in the analysis (n= 211). Participants who missed at least one of the follow-up points (the predominant reason being farming far away from the enrolment site) were not included in our study. Three samples (2 symptomatic and 1 asymptomatic) were excluded because no cytokines were detected in the plasma. For analysis of cytokines at the initial time point of our study with respect to correlation with persistent asymptomatic malaria, we employed a mixed linear model using the LME4 package [36]. Cytokine level was used as the response with conversion status as the fixed-effect of the model. We used sex and age as random effects in the model and ran the model separately for children ≤20 years old, adults >20 years old and all participants, regardless of age. To obtain p-value estimates from the t-values we used the lmerTest package [37]. P values were corrected for multiple comparisons using the Sattherthwaite correction. For analysis, parasite

densities were separated into three groups as follows, 1. submicroscopic parasitemia, 2. low levels

of microscopic parasitemia (parasitemia between 37.2 parasites/µl and 413.1 parasites/µl) and 3.

high levels of parasitemia (parasitemia> 413.1 parasites/µl, representing the median parasitemia in

the study population).

Results

Asymptomatic malaria prevalence in the study area

We carried out immunological analysis of a subset of 211 individuals from a previously reported study of 353 individuals screened for malaria using PCR, where 328 (92.9%) were positive for *Plasmodium falciparum* infection, of which 266 (81.1%) were asymptomatic and 62 (18.9%) were symptomatic [24]. This subset had complete sampling from the follow-up study, and included 142 individuals with asymptomatic infection, 61 symptomatic individuals and 8 non-infected individuals. At baseline when these individuals were first sampled, parasite densities were highly variable between the symptomatic and asymptomatic groups, and no significant difference was observed in the median parasite densities of the two groups at the initial time point of the study (**Table 1**). Age, sex, and hemoglobin levels were also not different across the study groups at this initial time point (**Table 1**).

F: female.

Non detectable infection (n=8)Asymptomatic (n=142) $(n=8)$ $(n=142)$ $(n=8)$ $(n=142)$ $(n=8)$ $(n=142)$ $(n=142)$ $(n=142)$ $(n=142)$ $(n=142)$ (20) $(n=142)$ (20) (120) (21) (22) (11) (22) (21) (22) (21) (22) (21) (22) (21) (22) (21) (22) (22) (21) (22) (22) (23) (21) (22) (21) (22) (21) (22) (21) (22) (21) (22) (21) (22) (21) (22) (21) (22) (21) (22) <t< th=""><th>Asymptomatic $(n=142)$ 20 >20 \leq 20 >20 \leq 22 \leq 94 \leq 48 \leq 2) 0.82 (42:51) 41.2 (14:34) 1.1 (2.68) 9 (2-19) 50 (22-86) 9 (2.14) 1.1 (2</th><th>Asymptomatic $(n=142)$ 1</th><th>Asymptomatic (n= 142)Symptomatic (n= 61$20$$20$20$20$$20$94$48$$42$2)$0.82 (42:51)$$41.2 (14:34)$$1.1 (22:20)$5$12 (4.9-14.3)$$13.1 (10.9-16)$$11.1 (6.8-14)$14)$11.1 (6.8-14)$$11.1 (6.8-14)$22.3 (21)$60.4 (29)$$9.5 (4)$575.7 (37.4-68190.5)$660.2$$764.1 (38.1-240457.1)$</th></t<>	Asymptomatic $(n=142)$ 20 >20 \leq 20 >20 \leq 22 \leq 94 \leq 48 \leq 2) 0.82 (42:51) 41.2 (14:34) 1.1 (2.68) 9 (2-19) 50 (22-86) 9 (2.14) 1.1 (2	Asymptomatic $(n=142)$ 1	Asymptomatic (n= 142)Symptomatic (n= 61 20 20 20 20 20 94 48 42 2) $0.82 (42:51)$ $41.2 (14:34)$ $1.1 (22:20)$ 5 $12 (4.9-14.3)$ $13.1 (10.9-16)$ $11.1 (6.8-14)$ 14) $11.1 (6.8-14)$ $11.1 (6.8-14)$ 22.3 (21) $60.4 (29)$ $9.5 (4)$ 575.7 (37.4-68190.5) 660.2 $764.1 (38.1-240457.1)$
	ptomatic = 142) > 20 ≤ 48 4 41.2 (14:34) 1.1 (2 50 (22-86) 9 (2 13.1 (10.9-16) 11.1 13.5 (38.3- 764.1 660.2) 2404	ptomatic Sympton = 142) $(n = 6)$ > 20 \leq 20 48 42 41.2 (14:34) 1.1 (22:20) 50 (22-86) 9 (2-20) 13.1 (10.9-16) 11.1 (6.8-14) 60.4 (29) 9.5 (4) 113.5 (38.3-660.2) 764.1 (38.1-660.2)	ptomatic Symptomatic (n=61) = 142) (n=61) >20 \leq 20 >20 \leq 20 48 42 41.2 (14:34) 1.1 (22:20) 50 (22-86) 9 (2-20) 28 (21-64) 0.219 13.1 (10.9-16) 11.1 (6.8-12.8 (9.4-16.8) 14) 16.8) 60.4 (29) 9.5 (4) 57.9 (11) 0.072 113.5 (38.3-764.1 (38.1-183.3(37.2-20.513)) 0.513 660.2) 240457.1) 5058.8)
> 20 > 20 48 41.2 (14:34) 50 (22-86) 13.1(10.9-16) 60.4 (29) 113.5 (38.3-660.2)	20 ≤ 8 4 14:34) 1.1 (2 2-86) 9 (2 0.9-16) 11.1 1 (29) 9.5 (38.3- 764.1).2) 2404	Sympton (n=6) 20 \leq 20 8 42 14:34) 1.1 (22:20) 2-86) 9 (2-20) 0.9-16) 11.1 (6.8- 14) (29) 9.5 (4) (38.3- 764.1 (38.1- 240457.1)	Symptomatic $(n=61)$ 20 ≤ 20 > 20 ≤ 20 8 42 19 14:34) 1.1 (22:20) 58.3 (7:12) 0.711 2-86) 9 (2-20) 28 (21-64) 0.219 0.9-16) 11.1 (6.8- 12.8 (9.4- 0.186) 14) 16.8) (29) 9.5 (4) 57.9 (11) 0.072 (38.3- 764.1 (38.1- 183.3 (37.2- 0.513) 0.2) 240457.1) 5058.8)
	Sympt (n= ≤20 42 1.1 (22:20) 9 (2-20) 11.1 (6.8- 14) 9.5 (4) 764.1 (38.1- 240457.1)	6 2	omatic 61) > 20 ≤ 20 19 58.3 (7:12) 0.711 28 (21-64) 0.219 12.8 (9.4- 0.180 16.8) 57.9 (11) 0.072 183.3(37.2- 0.513 5058.8)

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

Anti-parasite antibodies were inversely correlated with parasitemia but were not associated with asymptomatic parasite carriage Consistent with the hypothesis that host immunity increases with repeated exposure to malaria parasites, baseline parasite densities above the detection limit of microscopy decreased significantly with age (r = -0.49, P < 0.0001) (Figure 1A) but only in individuals aged 20 years and younger (r = -0.49, P < 0.0001) 0.39, P< 0.0001) (Figure 1B). Of the 142 participants who completed the follow-up study as designed, 78 (54.9%) remained asymptomatic during the 10-weeks follow-up period, whereas 63 (44.4%) developed malaria-associated fevers and 1 (0.7%) resolved the infection in the absence of any known antimalarial treatment. Based on the parasitemia distribution of those with microscopic *Plasmodium* infections at baseline the study population was divided into two groups aged ≤ 20 years and > 20 years old for further analyses. The proportion of submicroscopic infections was significantly higher (P<0.0001) in the older age group (age >20 years) at the baseline time point than in the younger age group (**Figure 1C**). At the baseline time point, median IgG levels against *P. falciparum* merozoite (ME) and schizont (SE) crude extracts were significantly higher in the >20-year age group than in the younger age group (P<0.0001) (**Figure 2A**). This was mirrored by IgG reactive to *P. falciparum* recombinant proteins EBA-175 (P=0.0250) and MSP-1₁₉ (P<0.0001) (Figure 2A). Additionally, In the younger age group IgG levels against merozoite (r= 0.22, P= 0.0077) and schizont (r= 0.29, P= 0.0004) crude extracts as well as against MSP-1₁₉ (r= 0.15, P= 0.0764) but not EBA-175 (r= 0.01, P= 0.8525) were positively correlated with age at the baseline time point (Figure 2B). A negative correlation was observed between IgG levels to P. falciparum merozoite and schizont extracts at baseline and parasite density measured at the same time point (Supplementary Figure 1). Indeed, the multilevel linear regression model adjusted for village and household levels, using IgG levels at the baseline and age as predictors, showed that only age was the independent predictor of *Plasmodium*

parasite densities in the study population (coef= -0.02, P= 0.0004 for age; coef= 0.01, P= 0.9170 for

ME; coef = -0.19, P = 0.1529 for SE; coef = -0.02, P = 0.4746 for EBA-175; coef = 0.02, P = 0.5362 for

Immunology of asymptomatic parasitemia

270

271

272

273

279

280

MSP-1₁₉). Median IgG levels were not significantly different between participants with sub-microscopic parasitemia and those with microscopic parasites at baseline (Supplementary Figure 2A), and no 274 significant difference was observed in the in vitro growth inhibition potential of inactivated plasma 275 from submicroscopic parasite carriers and that of microscopic carriers (Supplementary Figure 2B). 276 Both IgG antibody avidity (Supplementary Figure 3A&B) and growth inhibition potentials 277 (Supplementary Figure 2B) were similar in the two groups (P> 0.05). Together, these findings 278 suggest that anti-parasite antibodies may control parasite density levels by mechanisms other than direct inhibition of parasite growth in vivo.




Figure 1. Older individuals (>20 years) had a better control of parasite densities. A) Scatterplot showing a correlation between baseline parasite densities and age in all the infected individuals with parasitemia at the detection limit of light microscopy (n=138). Spearman rank correlation is presented as the best fit line and the coefficient (r), as well as the p-value (p), are shown. The red straight line was used to divide the study population into two groups aged ≤ 20 years and > 20 years old for further analyses. B) Scatterplot of correlation between baseline parasitemia detected by microscopy and age in different age groups (≤ 20 years and > 20 years) at the different time points of our study. Spearman rank correlation is presented as the best fit line and the coefficient (r), as well as the p-value (p), are shown for each age group. C) The pie chart shows the proportion of sub-microscopic infections (PCR+/microscopy-) versus microscopic (microscopy+) infections in each age group. PCR: Polymerase Chain Reaction.




Figure 2. Individuals >20 years old had more anti-parasite IgG at baseline. A) Data presented in the scatterplot represent baseline IgG antibody levels against different *P. falciparum* antigens (ME, SE, EBA-175 and MSP-1₁₉) within age groups. Median levels between age groups were compared by Wilcoxon signed-rank test and the p-values are shown on the graph. B) The scatterplots on B show the correlation between IgG levels against different *P. falciparum* antigens (ME, SE, EBA-175 and MSP-1₁₉) and age in different age groups (≤ 20 years and > 20 years). Spearman rank correlation is presented as the best fit line and the coefficient (r), as well as the p-values (p), are shown for each age group. SE: Schizont extract. ME: Merozoite extract. EBA-175: Erythrocyte binding antigen-175. MSP-1₁₉: Merozoite surface protein-1₁₉. OD: optical density.

Similarly, no significant difference was observed in malarial IgG antibody levels and avidity between participants with symptomatic or asymptomatic parasitemia (**Supplementary Figure 4A**), and no significant difference was seen in the blood parasitemia at the detection limit of microscopy (Supplemental Figure 4B; **Table 1**). However, the *in vitro* growth inhibition potential of plasma from asymptomatic malaria was greater than that of symptomatic individuals (P= 0.0245) despite no significant differences in the parasitemia amongst those with parasite levels that were detectable by microscopy (**Supplementary Figure 4B**). This may be a reflection of higher percentage of asymptomatic children with submicroscopic parasitemias (77.7%) compared to symptomatic children (90.5%) (**Supplementary Figure 4C**). Taken together, these data suggest that humoral responses other than IgG responses to the tested parasite antigens contribute to the maintenance of asymptomatic parasitemia in the study area.

Persistence of fluctuating asymptomatic parasitemia occurred in highly exposed individuals

without alteration in IgG levels

Of the 142 participants who completed the follow-up study as designed, 72 (50.7%) remained asymptomatic during the 10-weeks follow-up period, whereas 69 (48.6%) developed malaria-associated fevers and 1 (0.7%) resolved the infection in the absence of any known antimalarial treatment. Surprisingly, the propensity to convert was not associated with age (Figure 3A). Of the 72 participants who maintained chronic asymptomatic *P. falciparum* carriage, the proportion of submicroscopic infections remained similar in both age groups with most participants becoming microscopy positive on week 10 regardless of age (Figure 3B). Parasite densities fluctuated widely over the follow-up period from ultra-low parasitemia (sub-microscopic) to high parasitemia (Figure 3B), possibly due to variation in the infecting clones from new infections as this is a high transmission area (Figure 3C). However, no changes in IgG levels (Figure 3D) against all antigens tested were observed during persistent asymptomatic infections indicating that persistent asymptomatic parasitemia does not affect anti-*Plasmodium* IgG levels over this short 3-month time period. These

data suggests that asymptomatic carriage of *P. falciparum* occurs independently of circulating parasite numbers, even within highly-exposed individuals.




Figure 3. Asymptomatic malaria persisted in some individuals despite changes in the circulating parasite densities and population over time, but did not affect the antibody levels. A) The pie charts show the proportion of individuals with initial asymptomatic infection (cross-sectional) who resolved the infection (clearers), developed malaria-associated fever (uncomplicated malaria) or remained asymptomatic (persistent asymptomatic) over the 10-week follow-up period, according to age groups. B) Panel B displays the proportion of sub-microscopic/microscopic parasitemia in persistent asymptomatically infected individuals at three different time points (weeks 1, 4 and 11) according to age groups. Individuals who were RDT positive but without detectable micoroscopic parasitemia was detected are shown in pink. Of those who

had microscopic parasitemia, the line plots parasitemia across the 3 time points (**C**). To generate the line plots, the value 10 was assigned to submicroscopic parasitemia. The P values on the line plots refer to the comparison of the median parasitemia between two time points using the Wilcoxon test. **D**) Pie charts show the proportion of msp2 alleles (representing the clones) determined by nested PCR in individuals with persistent asymptomatic infection per week. Numbers represent the band sizes obtained. Blue slices represent the alleles only present at week 1. Red slices represent the alleles which appear at week 4. Green slices represent the allele only present at week 11. Grey slices represent the alleles that were present at all three sampling time points (bands of 375, 400, 475, 500, 520, 534, 540, 600, 620, 633. 680, 700, 800 bp). **E**) Data presented in the line plots represent the profile of IgG anti-*Plasmodium* antibody levels in each chronic asymptomatically infected individuals at three different time points (week 1, 4 and 11) in the two age groups. SE: Schizont extract. ME: Merozoite extract. EBA-175: Erythrocyte binding antigen-175. MSP-1₁₉: Merozoite surface protein-1₁₉. OD: optical density.

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

Parasite density was associated with inflammatory responses amongst younger individuals with asymptomatic malaria Given that *Plasmodium* parasites are associated with induction of inflammatory responses we measured the cytokine profiles of the 72 participants who had persistent asymptomatic carriage of P. falciparum across the course of our study. There was no particular cytokine signature that associated with asymptomatic carriage of *P. falciparum* in our study participants over the 11-week follow-up period (Figure 4A). Using a factor analysis of mixed data (FAMD) on cytokine data along with age and circulating parasite density, we found that levels of IL-10, TNF-α, the ratio of IL-10:IFN-γ and MCP-1, along with age and parasite density explained most of the variation in the peripheral cytokine response in asymptomatic individuals (Figure 4B). Multivariable analysis using age and parasitemia as predictors showed that age independently predicted the levels of TNF-α (coef= -0.31, P< 0.0001) peaking in younger study participants (**Figure 4C**). This is likely a reflection of circulating parasite densities which were higher in the younger group (Figure 1) and were also independently predictive of TNF- α levels (coef= 0.09, P< 0.0001) (**Figure 4D**). Circulating parasite density also independently predicted the levels of IL-10 (coef= 0.21, P< 0.0001) and MCP-1 (coef= 0.06, P= 0.01) with a significant increase in those who had high levels of parasitemia (parasitemia> 413.1 parasites/µl) relative to those who had low levels of microscopic parasitemia (parasitemia between 37.2 parasites/µl and 413.1 parasites/µl) (**Figure 4D**). This indicates that during asymptomatic carriage of *P. falciparum* circulating parasites simultaneously induce anti-inflammatory cytokine production to counteract the inflammatory effects of TNF-α. To determine which cytokines were dependent on parasite carriage we treated participants at week 11 of the study with ACT. This resulted in a significant decline in the IL-10 levels, but not TNF- α or MCP-1 levels, in the younger age group (Figure 5). Thus, the levels of IL-10 measured is a reflection of parasite carriage in the younger age group.

381

382

383

384

385

386




Figure 4. Cytokine responses were blunted with increased age and correlated with parasite densities at baseline. A) Hierarchical clustering of the standardized least-square means of 38 differentially expressed cytokines/chemokines/growth factors across the three sampling time points in participants with persistent asymptomatic infection (n= 72). B) Principal component of cytokines, age and parasitemia from FAMD (left graph) analysis. The right graph of B shows the contribution of each variable on the principal component 2 (dimension 2). C and D) box plots representing interquartile ranges (25th, median and 75th percentile, whisker

percentile (1st and 99th)) of the levels (Log10 pg/ml) of some main regulatory cytokines measured by Luminex according to age and parasite level groups at the baseline, respectively. Median levels of cytokines between two or more groups were compared by Wilcoxon rank-sum test and Kruskal-Wallis test, respectively. In Panel A, pairwise comparisons on neighboring groups were performed only when multiple comparisons were significant at p< 0.05. Parasite densities were groups in three groups as follows: submicroscopic parasitemia, low levels of microscopic parasitemia (parasitemia \leq 413.1 parasites/ μ l, representing the median parasitemia in the study population) and high levels of parasitemia (parasitemia> 413.1 parasites/ μ l). FAMD: Factor analysis of mixed data. *p< 0.05; **p< 0.001, ***p< 0.0001, ****p< 0.00001.




Figure 5. IL-10 and TNF- α levels were a reflection of parasite carriage, and the balance of inflammatory cytokines at baseline was associated with the maintenance of asymptomatic infections in the younger age, \leq 20 years. A) Box plots representing interquartile ranges (25th, median and 75th percentile, whisker percentile (1st and 99th)) of cytokine levels (Log₁₀ pg/ml) during persistent asymptomatic infections (week 1, 4 and 11) and after anti-malarial treatment (week 16). B) Box plots representing interquartile ranges (25th, median and 75th percentile, whisker percentile (1st and 99th)) of cytokine levels (Log₁₀ pg/ml) at the baseline between in those who developed uncomplicated malaria (UM; grey) and those who went on to display persistent asymptomatic malaria throughout the course of the study (PAM; blue). Analyses were performed including values from individuals with submicroscopic and microscopic parasitemia. Median cytokines levels between two or more groups were compared by Wilcoxon rank-sum test and Kruskal-Wallis test, respectively and significant between group differences indicated by the P value on the plot. In Panel A, pairwise comparisons on neighboring groups were performed only when multiple comparisons between the 4 groups were significant and are shown by the grey brackets. *p< 0.05 and ***p< 0.0001.

Maintenance of asymptomatic carriage of P. falciparum is associated with a more balanced

inflammatory cytokine ratio

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

There was no particular cytokine signature of asymptomatic individuals relative to symptomatic individuals in our study (Figure 6A). However, given that anti-inflammatory cytokines may be important in down-regulating the pathogenic inflammatory response in malaria, we tested the hypothesis that asymptomatic infection would be associated with higher levels of IL-10. To our surprise, at the initial time point of our study there was a non-significant trend towards higher levels of IL-10 in the symptomatic compared to asymptomatic participants (Figure 6B). This may be a reflection of higher inflammation levels in symptomatic individuals as other pro-inflammatory markers (IL-6 and MCP-1) were significantly higher in individuals with symptomatic malaria compared to those with asymptomatic *P. falciparum* infections in the younger age group (**Figure 6B**). There was an IL-10-skewed ratio of IL-10:TNF-α and IL-10:IFN-γ in the symptomatic group compared to the asymptomatic group in both age groups (Figure 6C). This is in agreement with previously published data in individuals with uncomplicated malaria and the IL-10 skewed ratio of IL-10 to TNF-α that can be measured in those with severe symptoms of malaria [38,39]. Multivariable logistic regression analysis showed that the IL-10:TNF-α ratio and IL-1RA levels were independently associated with developing symptoms during P. falciparum infection in this study (Supplementary Table S1).




Figure 6. IL-10 at baseline was associated with clinical malaria in the younger age group (≤ 20 years).

A) Hierarchical clustering (heatmap) of the standardized least-square means of 38 differentially expressed cytokines/chemokines/growth factors by infection status at the baseline of this study. **B** and **C** box plots represent interquartile ranges (25th, median and 75th percentile, whisker percentile (1st and 99th)) of the baseline cytokine levels (Log₁₀ pg/ml) measured by Luminex according to infection status. Analyses were performed including both individuals submicroscopic and microscopic parasitemia. Median levels of cytokines between two or three groups were compared by Wilcoxon rank-sum test and Kruskal-Wallis test, respectively.

In Panel B and C, pairwise comparisons were performed only when multiple comparisons were significant. P

values refer to the Kruskal-Wallis test comparison between the three groups. NI: Non-infected. AS:

Asymptomatic. SY: Symptomatic. *p< 0.05; **p< 0.001; ***p< 0.0001.

To further test the hypothesis that asymptomatic carriage of *P. falciparum* may be related to IL-10 production, we compared the cytokine ratios in the younger group who converted to symptomatic malaria throughout our study with those who remained asymptomatic. At the initial time point of the study there was a trend towards increased IL-10 levels in those who subsequently went on to develop uncomplicated malaria compared to those who experienced persistent asymptomatic malaria in both age groups. In the younger age group IL-10/pro-inflammatory cytokine ratios were significantly higher and IL-10-skewed (P= 0.0207 and P= 0.0111 for IL-10:TNF- α and IL-10:IFN- γ ratios, respectively) in the those developing uncomplicated malaria compared to those with persistent asymptomatic malaria in younger age group (**Figure 5B**). In this group those with persistent asymptomatic malaria had a ratios of 1.001±0.1355 for IL-10:TNF- α and 1.016±0.1794 for IL-10:IFN- γ) displaying an even balance of IL-10: proinflammatory cytokine. On the other hand adults did not have IL-10 skewed ratios with TNF- α or IFN- γ suggesting that a different or additional mechanism may facilitate the persistence of asymptomatic malaria in the older age group. Collectively this data suggests that IL-10 is not sufficient to dampen inflammatory responses in *Plasmodium* infection that lead to the fevers that define uncomplicated malaria.

Discussion

Significant gaps exist in the understanding of the contribution of anti-parasite and anti-disease immunity in the persistent asymptomatic parasite carriage in areas with high transmission of P. falciparum. Mathematical modelling of existing data indicates that asymptomatic P. falciparum infections could last for as long as 13-years [40] and field data documents the longevity of asymptomatic infections ranges from at least 2-9 months [7,41,42]. As we have previously

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

published, our study area has high rate of persistent asymptomatic parasite carriage over the 3 month time period of study [24]. However, a proportion of individuals in our study converted to symptomatic malaria as defined by the development of fever. Thus, we have assessed immune correlates of asymptomatic carriage of P. falciparum, as well as the predictors of conversion to symptomatic malaria. Consistent with the acquisition of immune response with age and exposure [13,43] in our study, older asymptomatic individuals had better control of circulating iRBCs with a greater proportion of submicroscopic infections than younger individuals. This was associated with an increase in the quantity of circulating anti-parasite IgG which appeared to saturate at around 20 years old. Our data is in agreement with an age-structured mathematical model of malaria transmission which showed that anti-parasite immunity which results in more rapid clearance of parasitemia has an approximate halflife of 20 years [44]. With a focus on the younger age group, there did not appear to be any correlations with respect to parasitemia levels and IgG levels or the avidity of the IgG. The in vitro invasionblocking capability of the plasma in young individuals had some functionality with respect to invasion blocking, but only at higher parasitemia levels. In this assay plasma factors other than IgG, such as IgM [45,46], may contribute to this observation and control of *P. falciparum* parasitemia in children. Collectively these data support a role for IgG in exerting control of iRBCs in P. falciparum infections, but it may not be the principal factor that dictates asymptomatic carriage of parasites in younger individuals. Surprisingly the proportion of those developing uncomplicated malaria over the course of our study was comparable between the younger and the older age groups, suggesting that the conversion from an asymptomatic to symptomatic infection is independent of age in highly exposed individuals. The reasons for this finding are not clear but may be related to heterogeneity of the circulating P. falciparum parasite population and emergence of highly inflammatory parasite clonotypes [47,48] that overcome the pyrogenic threshold of individuals. Consistent with the oscillation of parasite densities over time reported in a Vietnam cohort [7], parasitemia in persistent asymptomatic

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

infections in our study fluctuated widely and independently of IgG levels, and different clonotypes of *P. falciparum* were observed at different time points in this study. Cytokine profiles are considerably more dynamic than IgG responses. In line with the hypothesis that clinical immunity to malaria is mediated by a tempering of inflammation, previous studies have shown that the clinical outcome of malaria infection is largely dictated by the balance between proinflammatory and anti-inflammatory markers [17,18]. Although our study highlighted that carriage of P. falciparum across the duration of this study was associated with a consistent inflammatory response characterized by TNF-α, IL-10 and MCP-1, we found no obvious cytokine signature associated with the asymptomatic carriage of P. falciparum when compared to symptomatic individuals. Similar to findings in a study of visceral leishmaniasis [49], where increased IL-10 levels were the primary predictor of clinical conversion from asymptomatic to symptomatic visceral leishmaniasis, the conversion from asymptomatic to symptomatic malaria in our study was linked to increased baseline levels of IL-10 skewed ratios with TNF-α and IFN-γ in children at the initial time point of our study. Although IL-10 is known to exert anti-inflammatory effects that include inhibition of monocytes and macrophages in the production of inflammatory cytokines such as IL-6, TNF-α, and IL-1 [50], in agreement with a recent study from the Gambia [51] in our study IL-10 was associated with the presence of *Plasmodium* parasites. Given that higher levels of IL-6, IL-1RA and MCP-1 were also associated with symptomatic infections in the younger age group of our study, IL-10 levels are likely a consequence of increased inflammation. Notably, IL-10 induces IL1RA, a potent anti-inflammatory cytokine that regulates the pro-inflammatory actions of IL-1 [52] that has previously been shown to be associated with severity of malarial disease [53]. At the baseline time point in our study, we found that balanced inflammatory cytokine ratios were correlated with developing symptoms from P. falciparum infection in our younger age group. Specifically, those who developed uncomplicated malaria had a significant IL-10 skewed ratio at the initial time point compared to those who had

Immunology of asymptomatic parasitemia 518 persistent asymptomatic malaria. An IL-10 skewed ratio may indicate that an individual will shortly 519 develop symptoms of *P. falciparum* infection. 520 Most of the association between biomarkers and clinical malaria in this study were only found in the younger age group, but not in adults, indicating that the mechanisms of the protection against clinical 521 malaria may be different according to age. As such, more studies into how asymptomatic carriage of 522 523 *Plasmodium* occurs are warranted and should include non-antibody mediated mechanisms of parasite 524 control and clinical immunity which may be relevant in children. 525 Acknowledgements 526 We thank the field staff and, most importantly, residents of the Esse Health district in Cameroon who 527 participated in this study. 528 529 530 **Author contributions** 531 BF devised the experiments, performed the experiments, analyzed data, and wrote the paper; FM, MFA, EE, CD, GC, MK, RK and SK performed fieldwork and sample processing; MS and RP 532 533 provided cytokine kits and recombinant P. falciparum antigens, respectively and reviewed paper. RM 534 supervised the experiments and reviewed paper; LA and TL devised the experiments, supervised the 535 experiments, analyzed data, and wrote the paper. 536 **Financial Support:** 537 This work was supported by the Institute Pasteur International Division to LSA. 538 **Competing interests** 539 Authors declare no competing interests.

References

- 542 1. WHO. World Malaria Report. Genova; 2023.
- 2. Cibulskis RE, Alonso P, Aponte J, et al. Malaria: Global progress 2000 2015 and future challenges. Infect Dis Poverty. **2016**; 5(1):61.
- 3. Galatas B, Bassat Q, Mayor A. Malaria Parasites in the Asymptomatic: Looking for the Hay in the Haystack. Trends Parasitol. **2016**; 32(4):296–308.
- 547 4. Drakeley C, Gonçalves B, Okell L, Slater H. Understanding the Importance of Asymptomatic 548 and Low- Density Infections for Malaria Elimination. In: Manguin S, Dev V, editors. Malar
- Elimin Leap Forw [Internet]. InTech; 2018 [cited 2018 Sep 4]. Available from:
- http://www.intechopen.com/books/towards-malaria-elimination-a-leap-
- forward/understanding-the-importance-of-asymptomatic-and-low-density-infections-for-
- 552 malaria-elimination
- 553 5. Ashley EA, White NJ. The duration of Plasmodium falciparum infections. Malar J. **2014**; 13(1):500.
- 555 6. Slater HC, Ross A, Felger I, et al. The temporal dynamics and infectiousness of subpatent
- Plasmodium falciparum infections in relation to parasite density. Nat Commun [Internet]. 2019
- 557 [cited 2020 Jun 4]; 10. Available from:
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440965/
- 7. Nguyen T-N, Seidlein L von, Nguyen T-V, et al. The persistence and oscillations of submicroscopic Plasmodium falciparum and Plasmodium vivax infections over time in
- Vietnam: an open cohort study. Lancet Infect Dis. **2018**; 18(5):565–572.
- 562 8. Ademolue TW, Awandare GA. Evaluating antidisease immunity to malaria and implications for vaccine design. Immunology. **2018**; 153(4):423–434.
- 564 9. Ademolue TW, Awandare GA. Evaluating antidisease immunity to malaria and implications for vaccine design. Immunology. **2018**; 153(4):423–434.
- 566 10. Kijogi C, Kimura D, Bao LQ, et al. Modulation of immune responses by Plasmodium falciparum
- infection in asymptomatic children living in the endemic region of Mbita, western Kenya.
- 568 Parasitol Int. **2018**; 67(3):284–293.
- 569 11. Ouédraogo M, Samadoulougou S, Rouamba T, et al. Spatial distribution and determinants of
- asymptomatic malaria risk among children under 5 years in 24 districts in Burkina Faso. Malar
- 571 J. **2018**; 17:460.
- 572 12. Griffin JT, Hollingsworth TD, Reyburn H, Drakeley CJ, Riley EM, Ghani AC. Gradual
- acquisition of immunity to severe malaria with increasing exposure. Proc R Soc B Biol Sci.
- **2015**; 282(1801):20142657–20142657.
- 575 13. White M, Watson J. Age, exposure and immunity. eLife [Internet]. **2021** [cited 2021 Mar 31];
- 7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103766/
- 577 14. Boyle MJ, Reiling L, Feng G, et al. Human Antibodies Fix Complement to Inhibit Plasmodium
- falciparum Invasion of Erythrocytes and Are Associated with Protection against Malaria.
- 579 Immunity. **2015**; 42(3):580–590.

- 580 15. Duncan CJA, Hill AVS, Ellis RD. Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy? Hum Vaccines Immunother. **2012**; 8(6):706–714.
- 582 16. Garcia-Senosiain A, Kana IH, Singh S, et al. Neutrophils dominate in opsonic phagocytosis of P. falciparum blood-stage merozoites and protect against febrile malaria. Commun Biol. **2021**; 4(1):984.
- 585 17. Rovira-Vallbona E, Moncunill G, Bassat Q, et al. Low antibodies against Plasmodium falciparum and imbalanced pro-inflammatory cytokines are associated with severe malaria in Mozambican children: a case—control study. Malar J. **2012**; 11:181.
- 588 18. Andrade BB, Santos CJN, Camargo LM, et al. Hepatitis B Infection Is Associated with Asymptomatic Malaria in the Brazilian Amazon. PLOS ONE. **2011**; 6(5):e19841.
- 590 19. Kimenyi KM, Wamae K, Ochola-Oyier LI. Understanding P. falciparum Asymptomatic 591 Infections: A Proposition for a Transcriptomic Approach. Front Immunol [Internet]. **2019** [cited 592 2019 Dec 12]; 10. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6803459/
- 593 20. Guiyedi V, Bécavin C, Herbert F, et al. Asymptomatic Plasmodium falciparum infection in children is associated with increased auto-antibody production, high IL-10 plasma levels and antibodies to merozoite surface protein 3. Malar J [Internet]. **2015** [cited 2018 Feb 5]; 14(1). Available from: http://www.malariajournal.com/content/14/1/162
- 597 21. Gonçalves RM, Scopel KK, Bastos MS, Ferreira MU. Cytokine balance in human malaria: does 598 Plasmodium vivax elicit more inflammatory responses than Plasmodium falciparum? PLoS 599 One. **2012**; 7(9):e44394.
- Wilson NO, Bythwood T, Solomon W, et al. Elevated levels of IL-10 and G-CSF associated with asymptomatic malaria in pregnant women. Infect Dis Obstet Gynecol. **2010**; 2010.
- 602 23. Essangui E, Moukoko CEE, Nguedia N, et al. Demographical, hematological and serological 603 risk factors for Plasmodium falciparum gametocyte carriage in a high stable transmission zone 604 in Cameroon. PLOS ONE. **2019**; 14(4):e0216133.
- Fogang B, Biabi MF, Megnekou R, et al. High Prevalence of Asymptomatic Malarial Anemia and Association with Early Conversion from Asymptomatic to Symptomatic Infection in a Plasmodium falciparum Hyperendemic Setting in Cameroon. Am J Trop Med Hyg. **2021**; tpmd210316.
- 609 25. Biabi MFAB, Fogang B, Essangui E, et al. High Prevalence of Polyclonal Plasmodium 610 falciparum Infections and Association with Poor IgG Antibody Responses in a Hyper-Endemic 611 Area in Cameroon. Trop Med Infect Dis. **2023**; 8(8):390.
- Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg. **1995**; 52(6):565–568.
- Ranford-Cartwright LC, Taylor J, Umasunthar T, et al. Molecular analysis of recrudescent parasites in a Plasmodium falciparum drug efficacy trial in Gabon. Trans R Soc Trop Med Hyg. **1997**; 91(6):719–724.
- Quintana M del P, Ch'ng J-H, Zandian A, et al. SURGE complex of Plasmodium falciparum in
 the rhoptry-neck (SURFIN4.2-RON4-GLURP) contributes to merozoite invasion. PLOS ONE.

620 **2018**; 13(8):e0201669.

- 621 29. Heiber A, Spielmann T. Preparation of parasite protein extracts and western blot analysis. Bio-622 Protoc. **2014**; 4:e1136.
- 623 30. Bonnet S, Pêtres S, Holm I, et al. Soluble and glyco-lipid modified baculovirus Plasmodium 624 falciparum C-terminal merozoite surface protein 1, two forms of a leading malaria vaccine
- 625 candidate. Vaccine. **2006**; 24(33–34):5997–6008.
- 626 31. Perraut R, Varela M-L, Loucoubar C, et al. Serological signatures of declining exposure following intensification of integrated malaria control in two rural Senegalese communities.
- 628 PLoS ONE [Internet]. **2017** [cited 2019 Sep 8]; 12(6). Available from:
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469466/
- 630 32. Berry AA, Gottlieb ER, Kouriba B, et al. Immunoglobulin G subclass and antibody avidity
- responses in Malian children immunized with Plasmodium falciparum apical membrane antigen
- 632 1 vaccine candidate FMP2.1/AS02 A. Malar J. **2019**; 18(1):13.
- 633 33. Duncan EH, Bergmann-Leitner ES. Miniaturized Growth Inhibition Assay to Assess the Anti-
- blood Stage Activity of Antibodies. In: Vaughan A, editor. Malar Vaccines [Internet]. New
- York, NY: Springer New York; 2015 [cited 2019 Apr 30]. p. 153–165. Available from:
- 636 http://link.springer.com/10.1007/978-1-4939-2815-6_13
- 637 34. Efange NM, Lobe MMM, Keumoe R, Ayong L, Efange SMN. Spirofused
- tetrahydroisoquinoline-oxindole hybrids as a novel class of fast acting antimalarial agents with
- multiple modes of action. Sci Rep. **2020**; 10:17932.
- 640 35. R Core Team. R: A Language and Environment for Statistical Computing [Internet]. R Foundation for Statistical Computing; 2021. Available from: https://www.R-project.org/
- 36. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using Ime4. J
 Stat Softw. 2015;67(1):1-48.
- 645 37. Kuznetsova A, Brockhoff P, Christensen R. lmerTest: Tests in linear mixed effects models. 646 https://cranr-projectorg/package=lmerTest. 2016.
- 647
 648
 38. May J, Lell B, Luty AJ, Meyer CG, Kremsner PG. Plasma interleukin-10:Tumor necrosis factor
- (TNF)-alpha ratio is associated with TNF promoter variants and predicts malarial complications.
- 650 J Infect Dis. **2000**; 182(5):1570–1573.

- 651 39. Othoro C, Lal AA, Nahlen B, Koech D, Orago AS, Udhayakumar V. A low interleukin-10
- tumor necrosis factor-alpha ratio is associated with malaria anemia in children residing in a
- holoendemic malaria region in western Kenya. J Infect Dis. 1999;179(1):279-82. doi:
- 654 10.1086/314548. PubMed PMID: 9841855.
- 655 40. Ashley EA, White NJ. The duration of Plasmodium falciparum infections. Malar J. **2014**; 656 13(1):500.
- 41. Felger I, Maire M, Bretscher MT, et al. The Dynamics of Natural Plasmodium falciparum Infections. Gosling RD, editor. PLoS ONE. **2012**; 7(9):e45542.
- 659 42. Landier J, Kajeechiwa L, Thwin MM, et al. Safety and effectiveness of mass drug administration
- to accelerate elimination of artemisinin-resistant falciparum malaria: A pilot trial in four villages
- of Eastern Myanmar. Wellcome Open Res. 2017; 2:81.

690

- 662 43. Rodriguez-Barraquer I, Arinaitwe E, Jagannathan P, et al. Quantification of anti-parasite and anti-disease immunity to malaria as a function of age and exposure. eLife. **2018**; 7:e35832.
- 44. Filipe JAN, Riley EM, Drakeley CJ, Sutherland CJ, Ghani AC. Determination of the Processes
 Driving the Acquisition of Immunity to Malaria Using a Mathematical Transmission Model.
 PLOS Comput Biol. Public Library of Science; 2007; 3(12):e255.
- 45. Hopp CS, Sekar P, Diouf A, et al. Plasmodium falciparum-specific IgM B cells dominate in children, expand with malaria, and produce functional IgM. J Exp Med. **2021**; 218(4):e20200901.
- 670 46. Thouvenel CD, Fontana MF, Netland J, et al. Multimeric antibodies from antigen-specific 671 human IgM+ memory B cells restrict Plasmodium parasites. J Exp Med. **2021**; 672 218(4):e20200942.
- 673 47. Corrigan RA, Rowe JA. Strain variation in early innate cytokine induction by Plasmodium falciparum. Parasite Immunol. **2010**; 32(7):512–527.
- 48. Allan RJ, Rowe A, Kwiatkowski D. Plasmodium falciparum varies in its ability to induce tumor necrosis factor. Infect Immun. **1993**; 61(11):4772–4776.
- 677 49. Topno RK, Kumar R, Pandey K, et al. Early diagnostic marker for the conversion of asymptomatic to symptomatic visceral leishmaniasis. J Med Allied Sci. **2019**; 9(2):96–99.
- Waal Malefyt R de, Abrams J, Bennett B, Figdor CG, Vries JE de. Interleukin 10(IL-10) inhibits
 cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by
 monocytes. J Exp Med. 1991; 174(5):1209–1220.
- 682 51. Mooney JP, DonVito SM, Jahateh M, et al. "Bouncing Back" From Subclinical Malaria: 683 Inflammation and Erythrocytosis After Resolution of P. falciparum Infection in Gambian 684 Children. Front Immunol. **2022**; 13:780525.
- 685 52. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol. **1998**; 16:27–55.
- 53. John CC, Park GS, Sam-Agudu N, Opoka RO, Boivin MJ. Elevated serum levels of IL-1ra in children with P. falciparum malaria are associated with increased severity of disease. Cytokine.

 2008; 41(3):204–208.